Yes. Aetna's commercial medical plans cover Spravato (esketamine) for treatment-resistant depression in Massachusetts when prior authorization criteria are met. Aetna requires precertification through their Specialty Pharmacy program.
Across Lumin Health's 2026 commercial Spravato (esketamine) authorizations: 100% approval rate, with a median 4-day decision turnaround. Lumin Health's pre-submission medical-necessity review and standardized clinical documentation packet contribute to this outcome. Individual approval depends on plan-specific PA criteria — see Aetna's policy summary below.
Latest medical review on: May 5th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
Aetna covers Spravato for adults with treatment-resistant major depressive disorder when all of the following are documented (per Aetna Clinical Policy Bulletin 0950, last reviewed February 25, 2026):
Antidepressant classes Aetna recognizes (CPB 0950): Aminoketone (bupropion); Monoamine oxidase inhibitors (MAOIs); Noradrenaline and specific serotoninergic antidepressants (NASSAs); Selective serotonin reuptake inhibitors (SSRIs); Serotonin-norepinephrine reuptake inhibitors (SNRIs); Tricyclic antidepressants (TCAs); Serotonin modulators.
Aetna's augmentation definition (CPB 0950): Per the policy, augmentation therapy is one of: (a) two antidepressants with different mechanisms used concomitantly; (b) an antidepressant plus a second-generation antipsychotic; (c) an antidepressant plus lithium; or (d) an antidepressant plus thyroid hormone.
Evidence-based psychotherapies Aetna recognizes (CPB 0950): cognitive behavioral therapy (CBT), interpersonal therapy (IPT), supportive therapy (ST), or psychoeducational intervention (PEI).
Aetna's separate suicidal-ideation pathway. CPB 0950 covers Spravato for MDD with acute suicidal ideation or behavior under a distinct pathway with up to 4 weeks of initial coverage. The prescriber must represent that, in the absence of Spravato, “within the next 24 to 48 hours the member will require confinement in an acute care psychiatric institution.” This pathway does require concurrent oral antidepressant treatment.
Aetna's TRD dosing schedule (CPB 0950). Induction Phase (Weeks 1–4): twice weekly at 56 or 84 mg. Maintenance Phase (Weeks 5–8): once weekly at 56 or 84 mg. Maintenance Phase (Weeks 9+): every 2 weeks or once weekly, individualized to the least frequent dosing maintaining response.
Continued treatment is reauthorized in 6-month increments when documented improvement on standardized rating scales (BDI, HDRS, or MADRS) is sustained.
Massachusetts requires commercial insurers to cover mental health services on parity with medical/surgical benefits under Chapter 175 Section 47B and federal MHPAEA. This means Aetna cannot apply more restrictive prior authorization, visit limits, or cost-sharing to Spravato than to comparable medical treatments. For Massachusetts Medicaid (MassHealth) members, Spravato coverage follows the MassHealth Drug List criteria, which differ from commercial; Lumin Health verifies your specific plan at consultation.
Two Massachusetts statutes are particularly relevant when a commercial insurer reviews a Spravato prior authorization:
The “deemed granted” rule. Under 211 CMR 52.07, a Massachusetts commercial carrier that fails to respond to a complete prior authorization request within two business days is deemed to have granted the authorization. This applies to all major Massachusetts commercial carriers — Aetna, Blue Cross Blue Shield of Massachusetts, Cigna, Harvard Pilgrim Health Care, Mass General Brigham Health Plan, UnitedHealthcare, and the Group Insurance Commission's contracted carriers.
External review through the Office of Patient Protection. If your commercial insurer denies a Spravato authorization, you have the right to request external review by the Health Policy Commission's Office of Patient Protection (OPP). The filing window is four months from the final internal denial; OPP issues decisions within 45 days. Historically, more than 40% of OPP external reviews resolve in the patient's favor — an unusually patient-favorable rate compared with most states' insurance-department-administered review processes.
Lumin Health's Newton, Cambridge, Woburn, and Brookline locations handle Aetna Spravato authorizations end-to-end.
Spravato treatment at Lumin Health is available at all four Massachusetts locations: Newton, Cambridge, Woburn, and Brookline. All Lumin Health Spravato locations are REMS-certified per FDA requirements.
How Aetna compares with other major Massachusetts commercial payers on published Spravato prior authorization criteria:
Each linked cell opens the full Lumin Health Spravato coverage page for that payer.
Yes. Aetna requires precertification for Spravato across all commercial medical plans, regardless of state. Your prescriber submits the request to Aetna Specialty Pharmacy at 866-752-7021.
Two antidepressants from at least two different classes, each used for at least 8 weeks at the maximally tolerated dose within the past 5 years — plus an inadequate response to either augmentation therapy (8 weeks within the past 5 years) or evidence-based psychotherapy (CBT, IPT, ST, or PEI) during the current depressive episode.
In Lumin's typical experience, Aetna decisions return within 24–48 hours of complete documentation submission. Aetna's general PA decision timeline is up to 14 days for non-urgent requests, faster for expedited.
Lumin Health handles everything on your behalf so you don't have to worry. If your prior authorization is denied, our team manages the appeal process directly with Aetna — you don't need to navigate the paperwork or follow-ups.
Yes. Aetna's CPB 0950 covers Spravato for major depressive disorder with acute suicidal ideation under a separate criteria pathway, with up to 4 weeks of initial coverage when criteria are met.
Step 1 — File a Level 1 internal appeal. Deadline: 180 calendar days from receipt of the denial notice (per Aetna: "You have 180 days from when you get the notice of the denied claim, unless your plan brochure (or Summary Plan Description) gives you a longer period of time."). Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Call Member Services at the phone number on your Aetna ID card, or print and mail the Member complaint and appeal form available at aetna.com/individuals-families/member-rights-resources. For Spravato precertification specifically, Aetna routes through Aetna Specialty Pharmacy (phone 866-752-7021, fax 888-267-3277).
Step 2 — Peer-to-peer (P2P) review. Per Aetna: "Under certain circumstances, your physician may request a peer-to-peer review if they have a question or wish to discuss a medical-necessity precertification determination made by our medical director." For an appeal-stage P2P, your prescriber submits the appeal request form with a written note requesting peer-to-peer; a peer clinician at Aetna will conduct the review.
Step 3 — Expedited (urgent) appeal. Per Aetna: "You or your doctor may ask for an expedited appeal. Call the toll-free number on your Member ID card or the number on the claim denial letter." Federal urgent-care rules require Aetna to resolve expedited appeals within 72 hours when delay would jeopardize life, health, or the ability to regain function.
Appeal levels. Aetna plans provide either one or two levels of internal appeal — your specific plan documents control. Most commercial plans provide a single Level 1 internal appeal followed by external review.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. Aetna does not carve out behavioral-health appeals to a separate vendor for commercial members. Spravato precertification at Aetna routes through Aetna Specialty Pharmacy (the medical/specialty Rx benefit), and appeals follow the same pathway. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Aetna medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
Step 1 — File a Level 1 internal appeal. Deadline: 180 calendar days from receipt of the denial notice (per Aetna: "You have 180 days from when you get the notice of the denied claim, unless your plan brochure (or Summary Plan Description) gives you a longer period of time."). Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Call Member Services at the phone number on your Aetna ID card, or print and mail the Member complaint and appeal form available at aetna.com/individuals-families/member-rights-resources. For Spravato precertification specifically, Aetna routes through Aetna Specialty Pharmacy (phone 866-752-7021, fax 888-267-3277).
Step 2 — Peer-to-peer (P2P) review. Per Aetna: "Under certain circumstances, your physician may request a peer-to-peer review if they have a question or wish to discuss a medical-necessity precertification determination made by our medical director." For an appeal-stage P2P, your prescriber submits the appeal request form with a written note requesting peer-to-peer; a peer clinician at Aetna will conduct the review.
Step 3 — Expedited (urgent) appeal. Per Aetna: "You or your doctor may ask for an expedited appeal. Call the toll-free number on your Member ID card or the number on the claim denial letter." Federal urgent-care rules require Aetna to resolve expedited appeals within 72 hours when delay would jeopardize life, health, or the ability to regain function.
Appeal levels. Aetna plans provide either one or two levels of internal appeal — your specific plan documents control. Most commercial plans provide a single Level 1 internal appeal followed by external review.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Massachusetts external review is administered by the Health Policy Commission's Office of Patient Protection (OPP). Filing window: 4 months from the final internal denial. Decision timeline: 45 days. See Massachusetts state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. Aetna does not carve out behavioral-health appeals to a separate vendor for commercial members. Spravato precertification at Aetna routes through Aetna Specialty Pharmacy (the medical/specialty Rx benefit), and appeals follow the same pathway. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Aetna medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
